Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Pulmicort Generics Win a Negative for Teva, Canaccord Says

U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e-mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.